Overview
Research compounds tied to appetite, body composition, metabolic health, and lower-friction fat-loss support.
11 of 46 published compounds
$963.31
Fat Loss & Metabolism
body composition, metabolic support, waistline reduction, energy regulation
Goal hub next step
Build a weight loss & metabolism research path.
Use the quiz before choosing a compound, vendor, or PDF so the route reflects your goal, risk tolerance, and monitoring comfort.
Best options to research first
Ranked by evidence first, then risk. A research starting point, not a clinical recommendation.
Tesamorelin
FDA-approved GHRH analogue for HIV-associated lipodystrophy. Prescription only.
subcutaneous
Clinical endpoints assessed at 26 weeks in pivotal studies.
$600.00
3 tracked
Semaglutide
FDA-approved GLP-1 receptor agonist with strong human data for diabetes and obesity management.
subcutaneous, oral
Glucose effects emerge over the first weeks; weight-loss effects build across 3 to 12 months.
$120.00
1 tracked
Tirzepatide
Dual GIP/GLP-1 agonist with strong FDA-approved human data for glycemic control and weight loss.
subcutaneous
Metabolic effects begin within weeks; major body-composition changes accrue over months.
$200.00
1 tracked
Liraglutide
Once-daily GLP-1 receptor agonist with extensive clinical data for diabetes and obesity care.
subcutaneous
Metabolic and appetite effects begin within days to weeks; body-weight effects build over months.
0 tracked
AOD-9604
GH fragment studied in human obesity trials for lipolytic effects via β-adrenergic pathways.
oral, subcutaneous
Clinical trials measured outcomes over ~12 weeks; weight loss signals modest.
€963.31
2 tracked
Lower-risk options
Tesamorelin
FDA-approved GHRH analogue for HIV-associated lipodystrophy. Prescription only.
Semaglutide
FDA-approved GLP-1 receptor agonist with strong human data for diabetes and obesity management.
Tirzepatide
Dual GIP/GLP-1 agonist with strong FDA-approved human data for glycemic control and weight loss.
Liraglutide
Once-daily GLP-1 receptor agonist with extensive clinical data for diabetes and obesity care.
Higher-risk options
Injection-site reactions, headache, diarrhea, flushing, transient hypotension at higher doses.
Immunogenicity/impurity concerns (FDA); cortisol effects; decreased insulin sensitivity; glucose metabolism risk.
Endocrine spillover (ACTH, cortisol, prolactin); glucose metabolism concerns.
Immunogenicity risk (FDA); impurity concerns with unnatural amino acids; glucose/cortisol axis concerns.
Trusted vendors for metabolic and body-composition research
These vendors currently carry compounds in this goal category. Hub is the trust layer; outbound clicks happen after comparison.
Ignite Peptides
7 relevant compounds in hub
COA with order / verify current product report
third-party testing and COA documentation claimed by vendor; verify product-specific report
U.S. domestic territories only
affiliate: direct product page
Amino Club
6 relevant compounds in hub
product page COA viewer
third-party purity testing; product-level COA on page
US/ROW (verify current policy)
affiliate: public program
XL Peptides
6 relevant compounds in hub
testing reports on product page
third-party testing reports linked on product page
UK, Europe, and rest of world via vendor shipping options
affiliate: direct product page
Sources and review notes
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks - U.S. Food and Drug Administration - accessed 2026-05-15
Used for FDA compounding-risk context and peptide safety flags.
- The Prohibited List - World Anti-Doping Agency - accessed 2026-05-15
Used for athlete-facing WADA risk and peptide-class restrictions.
- Peptide therapeutics: current status and future directions - PubMed / Nature Reviews Drug Discovery - accessed 2026-05-15
Used for broad peptide-therapeutics background and evidence framing.